Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Current Liabilities: 2016-2025

Historic Total Current Liabilities for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $42.2 million.

  • UroGen Pharma's Total Current Liabilities rose 28.84% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 28.84%. This contributed to the annual value of $45.9 million for FY2024, which is 47.22% up from last year.
  • As of Q3 2025, UroGen Pharma's Total Current Liabilities stood at $42.2 million, which was down 11.16% from $47.5 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Total Current Liabilities peaked at $47.5 million during Q2 2025, and registered a low of $17.0 million during Q1 2021.
  • In the last 3 years, UroGen Pharma's Total Current Liabilities had a median value of $32.8 million in 2024 and averaged $34.6 million.
  • Per our database at Business Quant, UroGen Pharma's Total Current Liabilities dropped by 5.33% in 2022 and then surged by 59.45% in 2025.
  • Over the past 5 years, UroGen Pharma's Total Current Liabilities (Quarterly) stood at $22.4 million in 2021, then climbed by 6.86% to $23.9 million in 2022, then skyrocketed by 30.51% to $31.2 million in 2023, then surged by 47.22% to $45.9 million in 2024, then climbed by 28.84% to $42.2 million in 2025.
  • Its last three reported values are $42.2 million in Q3 2025, $47.5 million for Q2 2025, and $42.0 million during Q1 2025.